In the past few years, a role for apoptotic processes in the development of autoimmune diseases has been suggested. An increasing number of cellular proteins, which are modified during apoptosis, has been described, and many of these proteins have been identified as autoantigens. We have studied the effects of apoptosis on the La protein in more detail and for the first time demonstrate that this autoantigen is rapidly dephosphorylated after the induction of apoptosis. Dephosphorylation of the La protein was observed after induction of apoptosis by several initiators and in various cell types. Furthermore, we demonstrate that at least a subset of the La protein is proteolytically cleaved in vivo, generating a 45 kDa fragment. Dephosphorylation as well as cleavage of La is inhibited by ZnSO 4 as well as by several tetrapeptide caspase inhibitors, indicating that these processes require the activation of caspases. Dephosphorylation of La is inhibited by low concentrations of okadaic acid, suggesting that a PP2A-like phosphatase is involved. Generation of the 45 kDa fragment is consistent with proteolytic cleavage at amino acids 371 and/or 374. The possible significance of the apoptotic changes in the La protein for autoantibody production is discussed.
Introduction
In the past few years, a role for apoptosis in the development of autoimmune diseases has been suggested. 1, 2 Apoptosis is characterized by typical morphological changes in the dying cell, including chromatin condensation and membrane blebbing. Such manifestations are induced by biochemical modifications of nuclear and cytoplasmic proteins. An increasing number of cellular proteins which are cleaved during apoptosis have been described. Some of these proteins are structural proteins essential for maintaining nuclear and cytoplasmic architecture, while others are enzymes essential for repairing damaged cell components. Cleavage of these proteins, which is mediated by cysteine-proteases that are specifically activated during apoptosis (caspases) 3 results in the irreversible changes associated with apoptosis. Many of these cleaved proteins have been identified as autoantigens and include the U1-70K protein, which is a component of the U1 snRNP particle; 4 poly(ADP-ribose) polymerase (PARP); 5 hnRNP proteins C1 and C2; 6 and afodrin. 7 It has been postulated that cleavage of these proteins might unmask cryptic epitopes which are then presented to the immune system in such a way that tolerance to self proteins is broken (reviewed by Utz and Anderson). 8 Another mechanism by which proteins are fragmented, possibly resulting in the creation of novel epitopes, is via reactive oxygen radicals. Several autoantigens that are targeted in scleroderma (e.g., topoisomerase I, the large subunit of RNA polymerase II, and NOR 90) are uniquely susceptible to cleavage by reactive oxygen species in the presence of metal ions. 9 Four other types of posttranslational modifications which occur during apoptosis and which might lead to the generation of autoantibodies have been described. First, apoptotic hyperphosphorylation has been observed for U1 snRNP-associated serine/arginine family of splicing factors (SR proteins). 10 Phosphorylation may also play a role in autoantigenicity of RNA polymerase I and pol II components, which are only recognized by autoantibodies from SLE patients when they are phosphorylated.
in apoptotic cells, leading to changes in the exposure of these modified antigens to the immune system (reviewed by Utz and Anderson). 8 Although no other autoantigen modifications have so far been reported to occur during apoptosis, citrullination, methylation, deacetylation and dephosphorylation are modifications which may also contribute to the antigenicity of modified proteins.
One of the best studied autoantigens targeted in systemic lupus erythematosus (SLE) and Sjo È gren's syndrome (SS) is the La (SS-B) protein. La is an evolutionarily conserved phosphoprotein of 50 kDa, which under normal conditions accumulates in the nucleus. The La protein has been shown to bind, in most cases transiently, to all newly synthesized RNA polymerase III (pol III) transcripts and is involved in transcription of these RNAs. 18 La is necessary for correct and efficient termination of pol III transcription 19, 20 and has recently been identified as a pol III initiation factor. 21, 22 Phosphorylation of serine-366 has been shown to play an essential role in this process since La phosphorylated at this position appears to be transcriptionally inactive whereas dephosphorylated La is active. 23 However, a specific function for La in pol III transcription has recently been questioned by the results of in vitro transcription experiments in a Xenopus laevis system. 24 La plays a role in RNA processing of pol III transcripts as has been shown for tRNA 3'-and 5'-end maturation. 25 ± 27 La also appears to play an important role in internal initiation of translation 28, 29 and has been found associated with the 5' UTR of several mRNAs. 30 ± 32 Finally, an RNA chaperone activity for La, which might be consistent with all of its reported activities, has recently been proposed. 24, 25 It has been described previously that the subcellular localization of the La protein in human keratinocytes is altered after induction of apoptosis by UV irradiation. 1 In this study, the La protein appeared to be present in DNAcontaining apoptotic bodies, together with the ribonucleoprotein antigen Ro and the U snRNA-containing small nuclear RNPs. The involvement of the La protein in a large variety of biosynthetic processes makes this protein an attractive target for inactivation during early stages of apoptosis. Although acidic degradation of La generating a 43 kD cleavage product occurring in apoptotic as well as in non-apoptotic cell lysates has been described, 33 no changes specifically occurring during apoptosis have been reported for the La protein. In view of the functional relevance of the phosphorylation of La and the frequently observed cleavage of many (autoantigenic) proteins during apoptosis, we investigated these modifications for the La autoantigen in apoptotic cells. We demonstrate that the La protein is completely dephosphorylated upon exposure of the cells to multiple apoptotic stimuli. Dephosphorylation of La is inhibited by low concentrations of okadaic acid, suggesting that a PP2A-like phosphatase activity is involved. Furthermore, we demonstrate that at least a subset of the La protein is proteolytically cleaved. Dephosphorylation as well as cleavage of La is inhibited by Bcl-2, zinc and several tetrapeptide caspase inhibitors, suggesting that caspases are involved in these processes. Based upon their nature and position the molecular changes of the La protein reported in this study are likely to interfere with the biological function and subcellular distribution of this protein.
Results
Increasing evidence has been obtained demonstrating a relationship between apoptosis and the induction of autoimmunity. One of the main autoantigens recognized by sera of patients with systemic lupus erythematosus and Sjo È gren's syndrome is the La (SS-B) protein. Previously it has been reported that the La protein is relocalized to apoptotic bodies where it colocalizes with fragmented DNA. 1 To study the potential molecular changes in the La protein during apoptosis we used two stably transfected Jurkat cell lines, one overexpressing the apoptosis inhibitor Bcl-2 (Jurkat/Bcl-2) and the second a transfection vector control line (Jurkat/Neo). To induce apoptosis, the cells were treated with the monoclonal antibody 7C11, which cross-links and activates Fas.
The La (SS-B) autoantigen is dephosphorylated and cleaved early during apoptosis
The phosphorylation state of the La protein is of major importance for its function in the coordination of transcriptional and early post-transcriptional stages of pol III RNA biogenesis, which is mediated by a phosphorylation/dephosphorylation cycle. To study potential changes in the phosphorylation of the La protein during apoptosis, Jurkat cells were metabolically 32 P-labeled and treated with antiFas antibody. Cell extracts were prepared at various timepoints. The phosphorylation state of the La protein in these extracts was determined by immunoprecipitation of La from 32 P-labeled cell extracts using a monoclonal anti-La antibody (SW5) followed by SDS ± PAGE and Western blot analysis of the immunoprecipitate. Labeled proteins were detected by autoradiography. Analysis of the anti-La immunoprecipitate from the radiolabeled cell extracts revealed that during early stages of apoptosis the La protein was efficiently dephosphorylated ( Figure 1A) . Quantification of phosphorylated La using a phosphorimager demonstrates that within 2 h after anti-Fas treatment more than 50% of the radiolabeled phosphate was removed from the La protein in Jurkat/Neo cells. Although dephosphorylation was also observed in the Jurkat/Bcl-2 cells, the rate of dephosphorylation in these cells was much lower than that in the Jurkat/Neo cells ( Figure 1A , compare lanes 4 and 5 with lanes 11 and 12). Since complete medium was added to the cultures prior to apoptosis induction, in part the decrease of radiolabeled La protein might be a result of biological turnover of La phosphorylation. However, the lower dephosphorylation rate in Jurkat/Bcl-2 cells and the previously reported La phosphorylation half-life in K562 cells (3.6 h) 34 strongly suggest that La is dephosphorylated as a result of the induction of apoptosis. Western blot analysis using a polyclonal anti-La serum revealed that equal amounts of proteins were analyzed. Interestingly, in addition to the 50 kDa full-length La band a cleavage product of approximately 45 kDa appeared in anti-Fas treated cells ( Figure 1B ). This cleavage product was clearly detectable 3 h after anti-Fas treatment, and the relative amount of the cleavage product increased with longer incubation times. In some experiments a second apoptotic cleavage product was detected migrating between fulllength La and the 45 kDa cleavage product ( Figure 1B ; see also Figure 5B) ; however, the intensity of this band was always much lower than that of the 45 kDa band.
The efficiency of apoptosis induction was determined by flow cytometry, using Annexin V-FITC and propidium iodide (PI) staining. Four hours after the addition of anti-Fas antibody 80% of the Jurkat/Neo cells were stained by annexin V-FITC, indicating that these cells express phosphatidylserine, a marker of the early apoptotic state, 35 at their surface ( Figure 1C ). At this timepoint, only 19% of the Jurkat cells overexpressing Bcl-2 were annexin V-FITC positive. Staining by PI, indicative of a late apoptotic state of the cells, was hardly observed 8 h after anti-Fas treatment (only 9% of Jurkat/Neo and 5% of Jurkat/Bcl-2 were PI positive). However, when cells were cultured in the presence of anti-Fas antibody for 24 h, 66% of Jurkat/Neo cells and 48% of the Jukat/Bcl-2 cells were stained by PI. These results demonstrate that induction of apoptosis by anti-Fas treatment is very efficient in our Jurkat cells, whereas the apoptotic process is clearly retarded in the cell line overexpressing Bcl-2.
Additionally, as an internal control for the induction of apoptosis, we analyzed cleavage of the U1-70K protein using a patient serum reactive with U1-70K, one of the prototypic proteins known to be cleaved during apoptosis. 36 As shown in Figure 1D , cleavage of the U1-70K protein was observed by the appearance of the 40 kDa cleavage product 2 h after the addition of 7C11 ( Figure 1D, lane 7) . By 4 h, the majority of the U1-70K protein was cleaved ( Figure 1D, lane 8) . In contrast, in the Bcl-2 overexpressing cells a significant amount of uncleaved U1-70K protein was still present 8 h after anti-Fas addition ( Figure 1D , lane 5). These results are in good agreement with the efficiency of apoptosis induction as detected by flow cytometry ( Figure  1C ). In agreement with the inhibitory effect of Bcl-2 on apoptosis as determined by flow cytometry and U1-70K cleavage, we observed inhibition of La cleavage as well. As is demonstrated in Figure 1B , the 45 kDa fragment cleavage product was hardly detectable 3 h after anti-Fas addition to the Jurkat/Bcl-2 cells, ( Figure 1B , lane 4), although cleavage was clearly observed at later stages.
The results in Figure 1B show that cleavage of the La protein in apoptotic Jurkat cells is incomplete. To further characterize the degree of cleavage, the relative amounts of full-length La and the apoptotic cleavage product were quantified using a digital chemoluminescence imaging system. In Jurkat/Neo cells, up to 25% of the La protein was cleaved (at late stages during apoptosis), whereas in From these results we conclude that the La protein is rapidly dephosphorylated upon induction of apoptosis and that a subset of the La protein molecules is cleaved during apoptosis as well. Both dephosphorylation and cleavage are inhibited by Bcl-2.
To obtain stronger evidence for apoptotically induced dephosphorylation of La, a rabbit antiserum was raised against the phosphorylation site of La that has been mapped recently to Ser366 22 by immunization with a synthetic phosphorylated peptide. Western blotting revealed that this serum (SN305) appeared to be highly specific for La and completely dependent on the phosphorylation state of the protein (Figure 2A ). Treatment of the cell extract with alkaline phosphatase prior to blotting abolished recognition of La by this antiserum, while recognition by a control anti-La antibody was not affected, indicating that the lack of recognition by SN305 was due to the absence of phosphorylated amino acids and not to protein degradation. When the phosphorylation state of La in apoptotic cells was analyzed with this antiserum ( Figure 2B ) the results confirmed that La is specifically dephosphorylated after the induction of apoptosis, while recognition by a control anti-La antibody was not affected ( Figure 2C ).
A variety of apoptosis inducers leads to La dephosphorylation and cleavage in various cell types
To determine whether dephosphorylation and cleavage of the La protein are also observed with other apoptotic stimuli, we analyzed apoptotic cell extracts derived from human HeLa cells treated with actinomycin D (10 mM) or HEp-2 cells treated with anisomycin (10 mg/ml) by Western blot analysis using rabbit antiserum SN305 and a polyclonal anti-La patient serum. Consistent with the results for Jurkat cells, both dephosphorylation and cleavage were observed in apoptotic HeLa and HEp-2 cells (data not shown). Furthermore, cleavage of the La protein was analyzed in cell extracts derived from Jurkat cells treated with anisomycin (10 mg/ml), UV irradiation or the non apoptotic stimulus anti-CD3 by Western blot analysis. Consistent with the results for anti-Fas treated Jurkat cells, cleavage of La was observed in all cell extracts with the exception of the anti-CD3 treated Jurkat cell extracts (data not shown).
We next analyzed cleavage of the La protein in apoptotic (anisomycin treated) cells derived from mouse 3T3 cells, rat RBL cells and guinea-pig A104 cells and in freshly isolated mouse thymocytes rendered apoptotic by treatment with dexamethasone (1 mM) (Figure 3) . The resulting apoptotic cell extracts were analyzed for the appearance of the La cleavage product by Western blot analysis using an anti-La patient serum. In all cases La cleavage was observed, although the cleavage product of La in apoptotic mouse, rat and guinea-pig cell extracts migrated more slowly than the major human apoptotic cleavage product. Western blot analysis of La, isolated from HeLa S100 extract, with patient anti-La serum (lanes 3 and 6), with rabbit serum SN305, an antiserum raised against a phosphorylated peptide derived from the Ser366 phosphorylation site of La (lanes 2 and 5), and with the corresponding pre-immune serum (lanes 1 and 4). Isolated La protein was either directly analyzed (-AP, lanes 4 ± 6) or was treated with alkaline phosphatase prior to gel electrophoresis (+AP, lanes 1 ± 3). Dephosphorylation of the La protein abrogated the recognition of the protein by SN305 (compare lanes 2 and 5) while the reactivity of the patient serum shows that an equal amount of full-length La protein was present on the blot containing the dephosphorylated material (lanes 3 and 6). (B and C) Western blot analysis of apoptotic (anti-Fas induced) Jurkat cell extracts (lanes 1 ± 3: Jurkat/Bcl-2; lanes 4 ± 6: Jurkat/Neo) stained with rabbit serum SN305 (B) or the patient anti-La serum (C). Cell extracts were prepared at the indicated times after apoptosis induction. The positions of the 50 kDa fulllength La protein and the 45 kDa cleavage product are indicated on the right obtained after incubation of freshly isolated mouse thymocytes for 2, 4, 6 or 8 h in the presence of 1 mM dexamethasone (compared with mock treated cells as a control). Upon induction of apoptosis by dexamethasone treatment, a La cleavage product appeared within 2 h, and the relative intensity of this band increased over an 8 h period (Figure 3, lanes 7 ± 10) . Induction of apoptosis in all of these cells was monitored by cleavage of either the U1-70K protein or the 72 kDa component of the signal recognition particle (data not shown). 37 
Dephosphorylation of La is inhibited by a low concentration of okadaic acid
Recently it has been demonstrated that protein phosphatase 2A (PP2A) activity is increased 4.5-fold 6 h after antiFas induced apoptosis in Jurkat cells. 38 To determine whether this phosphatase activity might be involved in dephosphorylation of the La protein during apoptosis, we pre-incubated Jurkat/Bcl-2 and Jurkat/Neo cells for 1 h with 50 nM okadaic acid, a concentration which specifically inhibits PP2A activity but does neither inhibit nor induce apoptosis. 39 Following anti-Fas treatment, the cells were harvested at the indicated timepoints and the phosphorylation state of the La protein in untreated apoptotic cells and apoptotic cells treated with okadaic acid was determined by Western blotting using rabbit serum SN305. As is shown in Figure 4A , dephosphorylation of La was inhibited in cells treated with okadaic acid ( Figure 4A , compare lane 8 with lane 3), suggesting that PP2A is involved in the dephosphorylation of La during apoptosis. Analysis of these cell extracts by an anti-La serum revealed that cleavage of La was not inhibited by okadaic acid, strongly suggesting that cleavage occurs independently of dephosphorylation ( Figure 4B ). No differences in U1-70K cleavage were observed between extracts derived from cells treated with 50 nM okadaic acid and untreated cells (data not shown), confirming that this concentration of okadaic acid had no inhibitory effect on apoptosis. Thus, inhibition of La dephosphorylation is due to inhibition of PP2A rather than inhibition of apoptosis.
Effect of caspase inhibitors on dephosphorylation and cleavage of La
Since the activation of caspases is one of the major universal biochemical features of the execution phase of apoptosis, we investigated whether caspase activation was required for the dephosphorylation and cleavage of La. Therefore, we cultured Jurkat cells in the presence of several caspase inhibitors, including zinc sulphate, the tetrapeptide caspase inhibitors Ac-YVAD-CHO and Ac-DEVD-CHO (aldehyde derivatives) and the irreversible tetrapeptide inhibitors Ac-YVAD-CMK, Z-DEVD-FMK, Z-IETD-FMK, and Z-LEHD-FMK, for 1 h prior to induction of apoptosis by addition of anti-Fas antibody. Cells were harvested either immediately, or 4 or 8 h after addition of anti-Fas. Cell extracts were analyzed by Western blotting using either the phosphorylated La-specific antiserum SN305 or a polyclonal anti-La patient serum. Figure  5A demonstrates that dephosphorylation was slightly inhibited in Jurkat cells cultured in the presence of zinc sulphate ( Figure 5A , compare lanes 3 and 5). The addition of increasing amounts of Ac-DEVD-CHO resulted in increasing inhibition of La dephosphorylation ( Figure 5A , lanes 10 ± 13), while Ac-YVAD-CHO had no detectable effect on dephosphorylation of La ( Figure 5A , lanes 6 ± 9). In contrast, increasing amounts of the irreversible caspase inhibitor Ac-YVAD-CMK resulted in an almost complete inhibition of La dephosphorylation at a concentration of 20 mM ( Figure 5A , lanes 17 ± 20), which is most likely due to the fact that the irreversible inhibitor is a much more potent inhibitor than the aldehyde derivative in cultured cells. Also the other irreversible inhibitors, Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK resulted in inhibition of dephosphorylation ( Figure  5A , lanes 21 ± 32), albeit with different efficiencies. Note that the data shown in Figure 5 (lanes 1 ± 13 and lanes 14 ± 32) are derived from separate experiments, demonstrating that slight differences between the rate of the apoptotic process in different experiments might occur. Figure 3 Cleavage of the mouse La protein in apoptotic thymocytes. Freshly isolated mouse thymocytes were cultured in the absence (lanes 1 ± 5) or presence of 1 mM dexamethasone (lanes 6 ± 10) to induce apoptosis. After the indicated time periods (in h) cell lysates were analyzed by SDS ± PAGE/ Western blotting using a polyclonal anti-La serum. The positions of molecular weight markers and the mouse La protein and its cleavage product are indicated Figure 4 Inhibition of apoptotic La dephosphorylation by okadaic acid. Jurkat/Neo cells were rendered apoptotic by anti-Fas addition either in the absence (lanes 1 ± 5) or in the presence (lanes 6 ± 10) of 50 nM okadaic acid (oka). Cell extracts were prepared at the indicated time points and analyzed by Western blotting using SN305, the antiserum to the phosphorylated Ser366 epitope (A) and by a patient anti-La serum (B) Besides dephosphorylation, also apoptotic cleavage of La was affected in the presence of the inhibitors. Figure  5B demonstrates that La cleavage was completely inhibited in Jurkat cells cultured in the presence of zinc sulphate ( Figure 5B, lanes 4 ± 5) . The addition of Ac-DEVD-CHO also led to complete inhibition of cleavage ( Figure 5B , lanes 10 ± 13), while Ac-YVAD-CHO had no detectable effect on the cleavage of La ( Figure 5B , lanes 6 ± 9). The irreversible inhibitors all inhibited La cleavage, albeit with different efficiencies ( Figure 5B, lanes 14 ± 32) . The appearance of the 45 kDa and the 48 kDa cleavage products was equally sensitive to treatment of cells with the caspase inhibitors.
As a control for the inhibitory activity of the tetrapeptide inhibitors, the cell extracts were also analyzed for U1-70K cleavage, which is known to be sensitive to Ac-DEVD-CHO. 4, 36 Cleavage of the U1-70K protein was indeed inhibited by ZnSO 4 and the tetrapeptide inhibitors with the exception of Ac-YVAD-CHO, although the inhibitor Z-LEHD-FMK also in this case inhibited to a lesser extent (data not shown). Similarly, the activity of Ac-YVAD-CHO, which does not inhibit U1-70K cleavage was checked by the analysis of topoisomerase I cleavage, which was indeed inhibited by this reagent (data not shown).
Taken together, these results indicate that both dephosphorylation and cleavage of La are dependent on the activation of caspases or related proteases. Nevertheless, it should be noted that La cleavage is generally more strongly affected by caspase inhibitors than La dephosphorylation. Since the increase in phosphatase activity of PP2A in apoptotic cells is also dependent on caspase activation, 38 these results are consistent with PP2A being involved in the dephosphorylation of La. The use of bacterially expressed recombinant caspases-1,-2,-3,-8 and -9 failed to clarify a role for these caspases in the cleavage of the La protein (data not shown).
Determination of the putative La caspase cleavage site
Analysis of the amino acid sequence of the human La protein identified three putative caspase cleavage sites (i.e., amino acids 239 ± 242, 368 ± 371 and 371 ± 374). The apparent size of the apoptotic cleavage product suggests that cleavage might occur at Asp371 and/or Asp374. Most interestingly, these amino acids are located very close to Ser366, the major phosphorylation site of La. To investigate this in more detail we compared the electrophoretic mobility of the apoptotic cleavage product with that of several C-terminally truncated mutants of La which were produced by in vitro transcription and translation. A schematic representation of the La protein and the C-terminal deletion mutants of La is shown in Figure  6A . The in vitro translation products (La wt, LaDC383, LaDC380, LaDC366, LaDC355, LaDC344) were resolved in parallel with a non-apoptotic and an apoptotic (8 h after antiFas addition) Jurkat cell extract by SDS ± PAGE, and the proteins were detected by Western blotting using an anti-La patient serum. As is shown in Figure 6B , the apoptotic cleavage product ( Figure 6B , lane 5) migrated between the deletion mutants LaDC380 ( Figure 6B , lane 3) and LaDC366 ( Figure 6B, lane 6) . Thus, the electrophoretic behavior of the apoptotic cleavage product of La strongly suggests that La indeed is cleaved at either Asp371 or Asp374. An alignment of the available La sequences from other organisms that have been analyzed for cleavage of the La protein during apoptosis is shown in Figure 6C . 
Discussion
Previously, a subcellular relocalization of the La protein has been reported to occur in human keratinocytes during apoptosis initiated by UV irradiation. The La protein appeared to accumulate in nucleus-derived apoptotic bodies. 1 Here, we have studied molecular changes in the La protein occurring during apoptosis and demonstrate that the La protein is dephosphorylated very efficiently at Ser366. In addition a subset of La molecules is proteolytically cleaved, generating a 45 kDa fragment. These changes appear to be general for the apoptotic process since they were observed after induction of apoptosis by a variety of stimuli and in a variety of cell types. Both dephosphorylation and cleavage were inhibited by coincubation with zinc (an established apoptosis inhibitor), 40 as well as with several caspase inhibitors. Dephosphorylation of La is inhibited by low concentrations of okadaic acid, suggesting that a PP2A-like phosphatase is involved. Based upon the size of the cleavage product and the location of two overlapping putative caspase recognition sequences the cleavage site is most likely located at amino acids 371 or 374.
What could be the relevance of dephosphorylation and cleavage of La in apoptotic cells? The most well documented function of La is its activity in RNA synthesis by pol III. The La protein is involved in pol III transcription termination, 19, 20 transcript release 20 and pol III reinitiation. 21, 22 Accumulating evidence suggests that the cisacting oligo (dT) termination signal functions in RNA 3'-end formation of pol III transcripts, as well as in TFIIIC-mediated assembly and recycling of transcription complexes. 41, 42 This implies that proper termination facilitates efficient transcription. Full-length nascent transcripts are released from their template in a La-dependent fashion with simultaneous release of pol III from the termination complex, which is then available for reinitiation allowing additional rounds of RNA synthesis. 21 While transcriptional activity of La is inhibited by phosphorylation of Ser366, 23 dephosphorylated La, which is active in RNA pol III transcription, inhibits the early post-transcriptional event of 5'-end processing of pre-tRNA. 26 These data suggest a cycling role for La in the coordination of transcriptional and early post-transcriptional stages of pol III RNA biogenesis, which is mediated by a phosphorylation/dephosphorylation cycle. During apoptosis this phosphorylation cycle is apparently disrupted, which might have a dramatic effect on pol III RNA biogenesis.
In addition to these nuclear events La has also been implicated in cytoplasmic processes including the (internal) initiation of translation and the modulation of translational activity by inhibiting the activation of the double-stranded RNA-activated protein kinase PKR. 43 In part these activities may be due to the dsRNA unwinding activity of the La protein. 44 Both the N-and C-terminal regions of the protein have been shown to be essential for these activities. 45 Taken together, a variety of functional activities have been reported for La. Since all of these activities concern processes in which RNA is involved, it is tempting to speculate that La plays a universal role in all of them by acting as an RNA chaperone, a possibility that has recently been suggested by several investigators. 24, 25 Such a general activity would also make the La protein an attractive target for early inactivation during apoptosis, which might result in the simultaneous inhibition of many biosynthetic processes. Of particular interest is the putative apoptotic release of the inhibition of PKR activation due to dephosphorylation and/or cleavage of La, which would result in elevated levels of activated PKR, a protein kinase that may play a central role in early stages of apoptosis. 46, 47 Many proteins have been reported to be cleaved during apoptosis, and this number is still growing. 48 Cleavage of these proteins in most, if not all cases is a result of the activation of caspases, cysteine proteases with aspartic acid substrate specificity. Many of the caspase targets have important functions such as maintenance of (sub)cellular architecture or repair of damaged cells, and their cleavage is thought to account for the irreversible cellular changes associated with apoptosis. Apoptotic cleavage of La did not proceed to completion in the cells examined (up to 25% of the molecules were cleaved at late stages of apoptosis). A possible explanation might be the involvement of La in so many different biosynthetic processes, which might imply that only a subset of the La protein is accessible for caspase activity. Removal of the C-terminal amino acids may have important functional implications for the protein. Previously, we have shown that the nuclear localization signal (NLS) of the La protein resides in the extreme C-terminal end of the molecule (aa 383 ± 408), 49 implying that cleavage at aa 371 or 374 would remove the complete NLS from the protein. We have observed by immunofluorescence that the (re)distribution of La in apoptotic Jurkat cells is very similar to that seen in apoptotic keratinocytes. 1 Also in Jurkat cells La appeared to accumulate in apoptotic bodies during apoptosis (our unpublished observations). Due to the lack of an antibody specifically recognizing the apoptotic La cleavage product, the relatively low level of cleavage product at early stages of apoptosis and the characteristic morphological changes occurring in apoptotic cells, no conclusions could be drawn on the effect of the removal of the NLS on the subcellular distribution of La.
The significance of La cleavage for the progression of the apoptotic process is unknown. However, the relatively late onset of La cleavage during the apoptotic process and the fact that the majority of La molecules is not cleaved argue against a significant role. It is clear that, if cleavage of the La protein is a key event in the execution phase of apoptosis, this only holds true for a subset of the La molecules. Given the variety of processes in which La has been proposed to play a role, it would be interesting to investigate which features determine whether a La molecule is cleaved or not cleaved. Interestingly, Ser366 is located very close to the putative caspase cleavage sites, raising the intriguing possibility that dephosphorylation of La at Ser366 is required for cleavage to occur. However, since okadaic acid inhibited dephosphorylation of La but did not affect cleavage of the La protein, cleavage and dephosphorylation appear to be two independent processes. This implies that in principle also the 45 kDa cleavage product might be phosphorylated. The fact that no phosphorylated cleavage product was detected in apoptotic cells is most likely due to both the rate and the degree of dephosphorylation, both being much higher than for cleavage. Although in the presence of okadaic acid the conditions might have been more favorable to detect a phosphorylated cleavage product, no such protein was detected. This might be explained by either the only partial inhibition of dephosphorylation (the experimental setup did not allow the usage of higher concentrations of phosphatase inhibitor) or by the possibility that the epitope(s) recognized by rabbit serum SN305 was disrupted by the cleavage. Attempts to develop an in vitro apoptotic cleavage assay for La have been unsuccessful, which complicates a more precise determination of the cleavage site and identification of the caspase(s) involved.
An alignment of the available La sequences of those organisms that have been analyzed for cleavage of the La protein during apoptosis is shown in Figure 6C . In the Cterminal region of both mouse and rat La two putative caspase cleavage sites are present, one at position 377 ± 380 (DDDD) and one at position 391 ± 394 (DGRD). If the latter site is the actual caspase cleavage site, which is expected to be a much better caspase substrate than the former, 50 this might explain the difference in electrophoretic mobility observed between the 45 kDa cleavage products of human La on the one hand and the approximately 48 kDa cleavage product of mouse ( Figure  3 ), rat and guinea-pig La on the other. In addition, the minor cleavage product of human La (approximately 48 kDa) migrating between the 45 kDa cleavage product and the full-length human La protein may correspond to the cleavage product of mouse, rat and guinea-pig La, since another putative caspase cleavage site (387-EETD-390) is present at an equivalent position in the human sequence ( Figure 6C ). 50 Surprisingly, in both the mouse and rat La proteins Ser366 homologs are lacking. Nevertheless, Ser366 phosphorylation in the human La protein, which resides in a CKII consensus sequence ((S/ T)XX(D/E)), 51 has been unequivocally demonstrated and phosphorylation of this residue appeared to regulate the transcription factor activity and to affect pre-tRNA processing. 23, 25, 27 In both mouse and rat La a threonine is present at amino acid 386 flanked by the amino acids RFD, which thus might represent a CKII phosphorylation site located at an almost equivalent position. Since the Ctermini of La proteins from several species (Ser366 conservation is observed in bovine, rabbit and Xenopus laevis La) contain CKII consensus sites, the physiological significance of this phosphorylation site is likely to be conserved as well.
Dephosphorylation of several proteins is known to occur during apoptosis, including the retinoblastoma protein, a protein involved in cell cycle progression, 52 ± 55 FAST kinase, which phosphorylates the TIA-1 RNA binding protein upon its dephosphorylation 56 and the family of ERM (Ezrin/Radixin/Moesin) proteins, which play a role in microvillar formation. Apoptotic dephosphorylation of autoantigens has not yet been reported, although several hyperphosphorylated SR proteins appear to stably associate with the U1 snRNP during cell death. 10, 58 La represents the first autoantigen that is rapidly dephosphorylated during cell death. Two candidate phosphatases that are activated during apoptosis have been recently described, including mitogen-activated protein kinase phosphatase-1 59 and protein phosphatase 2A. 38, 60 Interestingly, PP2A was identified in a yeast 2 hybrid screen using caspase-3 as bait. Upon induction of apoptosis in Jurkat cells, the regulatory subunit of PP2A is cleaved by caspase-3, thereby increasing PP2A activity 4.5-fold 6 h after antiFas treatment. The effects on PP2A could be prevented by the caspase inhibitors Ac-DEVD-CHO and Ac-DEVD-FMK. Inhibition of La dephosphorylation by low concentrations of okadaic acid and by the caspase inhibitor Ac-DEVD-CHO support the hypothesis that PP2A or a related phosphatase is involved.
It has been proposed that post-translational modifications, such as proteolysis, phosphorylation, modification by transglutaminase, ubiquitination and poly(ADP-ribosyl)ation may produce novel epitopes or enhance the exposure of the (modified) antigens to the immune system (reviewed by Utz and Anderson 8 ). However, only a subset of the known autoantigens is cleaved during apoptosis and even fewer autoantigens are known to undergo other types of modifications. In view of the present findings for La it can be anticipated that unique apoptotic modifications will be found for other autoantigens in the near future. Additional studies are required to investigate whether dephosphorylation and cleavage of the La protein during apoptosis might play a crucial role in the breaking of immunological tolerance to this protein.
Materials and Methods

Cell culture
Jurkat cells, with Bcl-2 (Jurkat/Bcl-2) or without Bcl-2 (Jurkat/Neo) overexpression, were grown in RPMI (Gibco BRL) medium supplemented with 10% heat-inactivated fetal calf serum, 200 mg/ml G418 (Gibco BRL), 1 mM b-mercapthoethanol, 1 mM sodium-pyruvate and penicillin and streptomycin. Freshly isolated mouse thymocytes were grown in RPMI medium supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium-pyruvate and penicillin and streptomycin. HeLa cells, HEp-2 cells, Rat basophilic leukemia cells (RBL), mouse 3T3 cells and guinea-pig A104 cells were grown in DMEM supplemented with 10% heat-inactivated fetal calf serum and penicillin and streptomycin. Cells were cultured in 5% CO 2 at 378C.
Preparation of apoptotic cell extracts
Jurkat cells were treated with an anti-Fas monoclonal antibody 7C11, a kind gift of Dr. M Robertson (Indiana University, Bloomington, IN, USA), 10 mg/ml anisomycin, anti-CD3, or UV irradiation as described 37 and cells were incubated at 378C for the indicated time periods prior to harvesting. HeLa cells were treated with 10 mM actinomycin D, HEp-2 cells, RBL cells, 3T3 cells and A104 cells were treated with 10 mg/ml anisomycin, freshly isolated mouse thymocytes were treated with 1 mM dexamethasone. Cells were lysed in NP-40 lysis buffer (25 mM Tris, pH 7.5, 100 mM KCl, 0.25 mM DTE 10 mM MgCl 2 , 1% NP-40, protease inhibitor cocktail from Boehringer Mannheim) for 30 min on ice. After centrifugation for 15 min at 12 0006g, supernatants were analyzed by Western blotting. Monolayer cells were trypsinized, washed with PBS and lysed as above. For experiments utilizing the phosphatase inhibitor and caspase inhibitors, Jurkat cells were cultured in the presence of either 50 nM okadaic acid, 2% DMSO, 2 mM ZnSO 4 , 10 or 100 mM Ac-YVAD-CHO (Calbiochem), 10 or 100 mM Ac-DEVD-CHO (Calbiochem), 2 or 20 mM Ac-YVAD-CMK (Calbiochem), 2 or 20 mM Z-DEVD-FMK (Calbiochem), 2 or 20 mM Z-IETD-FMK (Calbiochem) or 2 or 20 mM Z-LEHD-FMK (Calbiochem). Subsequently, apoptosis was induced by the addition of anti-Fas monoclonal antibody followed by harvesting after incubation as indicated and lysis as described above.
Flow cytometry
To monitor the induction of apoptosis in Jurkat cells by anti-Fas treatment, cells were stained with annexin V conjugated to fluorescein isothiocyanate (FITC) (1 mg/ml) in RPMI/10% fetal calf serum/2.5 mM CaCl 2 for 2 min at room temperature followed by propidium iodide (5 mg/ml) staining for 10 min at 48C. Cell staining was determined using a Coulter Epics Elite flow cytometer.
Western blot analysis
Cell extracts were fractionated by SDS ± PAGE (10%) and blotted onto a nitrocellulose filter. After blocking the filters in wash buffer (5% skimmed milk, PBS, 0.1% NP-40) for 1 h at room temperature, filters were incubated with patient serum C25 (anti-La), H42 (anti-U1-70K), Z28 (anti-topoisomerase I) (1/5000) or rabbit serum (SN305) (1/2500) in wash buffer for 1 h at room temperature. After washing three times for 15 min, binding of antibodies was visualized by incubation with peroxidase-conjugated rabbit anti-human antibodies or swine anti-rabbit antibodies (Dako) followed by chemoluminescence detection. Rabbit antisera reactive with phosphorylated serine-366 of the human La protein were raised against a peptide corresponding to aa 361 ± 371 of the human La protein (H 2 N-CKTKFASDDEHD-CONH 2 ) carrying a phosphorylated serine (Eurogentec, Seraing, Belgium).
Metabolic labeling and immunoprecipitation
Jurkat/Bcl-2 and Jurkat/Neo cells were incubated at a density of 2610 6 cells/ml in labeling medium (RPMI without phosphate (ICN), 2 mM glutamax (Gibco-BRL), 5% dialyzed fetal calf serum 1 mM sodium-pyruvate, 10 mM HEPES (pH 7.4) and penicillin and streptomycin).
32 P-labeled orthophosphate was added at a concentration of 33 mCi/ml. After incubating the cells at 378C for 18 h, an equal volume of RPMI (Gibco BRL) medium supplemented with 10% heatinactivated fetal calf serum, 200 mg/ml G418 (Gibco BRL), 1 mM bmercapthoethanol, 1 mM sodium-pyruvate, 10 mM HEPES (pH 7.4) and penicillin and streptomycin was added. Cells were treated with an anti-Fas monoclonal antibody 7C11 and incubated at 378C. Radiolabeled cells were either solubilized in NP-40 lysis buffer immediately or after incubation for 1, 2, 3, 4, 6 or 8 h. Cell lysates were incubated on ice for 30 min, followed by centrifugation for 15 min at 48C at 12 0006g. To immunoprecipitate radiolabeled La protein, protein A-agarose beads were incubated with an anti-La monoclonal antibody (SW5) by rotation for at least 1 h in IPP 500 (10 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.05% NP-40) followed by washing twice with IPP 500 and twice with TKED (10 mM Tris-HCl (pH 8.0), 100 mM KCl, 1 mM DTE, 1 mM EDTA, 0.05% NP-40). After rotating the coated beads with the radiolabeled extracts in TKED for 2 h at 48C, the beads were washed three times with TKED and radiolabeled proteins were analyzed by 10% SDS-polyacrylamide gel electrophoresis and subjected either to autoradiography or Western blotting.
In vitro transcription and translation
In vitro transcription and translation were performed as described. 49, 61 Wild-type La and LaDC380 protein were produced after linearization with HindIII and AvaII, respectively. Mutants LaDC383 and LaDC355 were made by linearizing La383/4 and La355/6 with BamHI, LaDC366 was made by linearizing La366/7 with NarI and LaDC344 was made by linearizing La344/6 with ClaI. 
